SGMO240816C500
- 0.42
- +0.04+10.53%
Sangamo Therapeutics Newsroom
Earnings Update: Here's Why Analysts Just Lifted Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target To US$3.80
Q2 2024 Sangamo Therapeutics Inc Earnings Call
Earnings Call: Sangamo Therapeutics Extends Cash Runway Into 2025
RBC Capital Remains a Hold on Sangamo Biosciences (SGMO)
Roche Strikes New Deal With Sangamo to Tackle Alzheimer's
Sangamo Therapeutics, Inc. (SGMO) Q2 2024 Earnings Call Transcript
Express News | Sangamo Therapeutics Expects FY24 GAAP Basis Total Operating Expenses Of Approximately $150M - $170M
Sangamo in Global Epigenetic Regulation and Capsid Delivery License Agreement With Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases >SGMO
Sangamo Eligible to Earn Up to $1.9 B in Milestone Payments, Plus Tiered Royalties on Net Sales >SGMO
Sangamo Expects to Get $50 M in Near-Term Upfront License Fees and Milestone Payments >SGMO
Sangamo Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Sangamo Therapeutics Q2 Net Income USD -36.128 Million
Express News | Sangamo Therapeutics Q2 EPS USD -0.18 Vs. IBES Estimate USD -0.15
Express News | Sangamo Therapeutics Q2 Adjusted Operating Expenses USD 31.9 Million
Express News | Sangamo Therapeutics Q2 Operating Income USD -37.084 Million
Express News | Sangamo Therapeutics Q2 Revenue USD 356 Thousand Vs. IBES Estimate USD 8.26 Million
Express News | Sangamo Therapeutics Q2 Operating Expenses USD 37.4 Million
Express News | Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
Sangamo Therapeutics 2Q Rev $356,000 >SGMO
Why Sangamo Therapeutics Stock Is Soaring